Molecular markers for bladder cancer

The road to a multimarker approach

Marc Birkhahn, Anirban P. Mitra, Richard J Cote

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Bladder cancer is the seventh most common malignancy worldwide, with almost 14,000 patients dying from this disease in the USA alone. Because of the need for long-term and frequent follow-up, as well as the paucity of sensitive and specific noninvasive tests, bladder cancer management has the highest cost per patient among all cancer types. Several molecular markers, especially members of the cell cycle regulation and apoptosis pathways, have been investigated. However, no individual marker has been prognostically powerful enough to change clinical management. The combined analysis of a panel of markers spanning different pathways is the most promising approach. We give an overview of the most important molecular markers functioning in crucial pathways and focus on their role in multimarker analysis.

Original languageEnglish
Pages (from-to)1717-1727
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume7
Issue number12
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Neoplasms
Cell Cycle
Apoptosis
Costs and Cost Analysis

Keywords

  • Apoptosis
  • Marker panel
  • Multimarker analysis
  • p53
  • Protein expression
  • Retinoblastoma
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Molecular markers for bladder cancer : The road to a multimarker approach. / Birkhahn, Marc; Mitra, Anirban P.; Cote, Richard J.

In: Expert Review of Anticancer Therapy, Vol. 7, No. 12, 01.12.2007, p. 1717-1727.

Research output: Contribution to journalArticle

@article{abbe4b82723546c782cd961654638eba,
title = "Molecular markers for bladder cancer: The road to a multimarker approach",
abstract = "Bladder cancer is the seventh most common malignancy worldwide, with almost 14,000 patients dying from this disease in the USA alone. Because of the need for long-term and frequent follow-up, as well as the paucity of sensitive and specific noninvasive tests, bladder cancer management has the highest cost per patient among all cancer types. Several molecular markers, especially members of the cell cycle regulation and apoptosis pathways, have been investigated. However, no individual marker has been prognostically powerful enough to change clinical management. The combined analysis of a panel of markers spanning different pathways is the most promising approach. We give an overview of the most important molecular markers functioning in crucial pathways and focus on their role in multimarker analysis.",
keywords = "Apoptosis, Marker panel, Multimarker analysis, p53, Protein expression, Retinoblastoma, Urothelial carcinoma",
author = "Marc Birkhahn and Mitra, {Anirban P.} and Cote, {Richard J}",
year = "2007",
month = "12",
day = "1",
doi = "10.1586/14737140.7.12.1717",
language = "English",
volume = "7",
pages = "1717--1727",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Molecular markers for bladder cancer

T2 - The road to a multimarker approach

AU - Birkhahn, Marc

AU - Mitra, Anirban P.

AU - Cote, Richard J

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Bladder cancer is the seventh most common malignancy worldwide, with almost 14,000 patients dying from this disease in the USA alone. Because of the need for long-term and frequent follow-up, as well as the paucity of sensitive and specific noninvasive tests, bladder cancer management has the highest cost per patient among all cancer types. Several molecular markers, especially members of the cell cycle regulation and apoptosis pathways, have been investigated. However, no individual marker has been prognostically powerful enough to change clinical management. The combined analysis of a panel of markers spanning different pathways is the most promising approach. We give an overview of the most important molecular markers functioning in crucial pathways and focus on their role in multimarker analysis.

AB - Bladder cancer is the seventh most common malignancy worldwide, with almost 14,000 patients dying from this disease in the USA alone. Because of the need for long-term and frequent follow-up, as well as the paucity of sensitive and specific noninvasive tests, bladder cancer management has the highest cost per patient among all cancer types. Several molecular markers, especially members of the cell cycle regulation and apoptosis pathways, have been investigated. However, no individual marker has been prognostically powerful enough to change clinical management. The combined analysis of a panel of markers spanning different pathways is the most promising approach. We give an overview of the most important molecular markers functioning in crucial pathways and focus on their role in multimarker analysis.

KW - Apoptosis

KW - Marker panel

KW - Multimarker analysis

KW - p53

KW - Protein expression

KW - Retinoblastoma

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=37349089371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349089371&partnerID=8YFLogxK

U2 - 10.1586/14737140.7.12.1717

DO - 10.1586/14737140.7.12.1717

M3 - Article

VL - 7

SP - 1717

EP - 1727

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 12

ER -